These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

711 related articles for article (PubMed ID: 27486710)

  • 1. Genetics of Parkinson's disease: a review of SNCA and LRRK2.
    Konno T; Siuda J; Wszolek ZK
    Wiad Lek; 2016; 69(3 Pt 1):328-32. PubMed ID: 27486710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical molecular genetics for PARK8 (LRRK2)].
    Tomiyama H; Hatano T; Hattori N
    Brain Nerve; 2007 Aug; 59(8):839-50. PubMed ID: 17713120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LRRK 2 gene mutations in the pathophysiology of the ROCO domain and therapeutic targets for Parkinson's disease: a review.
    Chen ML; Wu RM
    J Biomed Sci; 2018 Jun; 25(1):52. PubMed ID: 29903014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autosomal dominant Parkinson's disease: Incidence of mutations in LRRK2, SNCA, VPS35 and GBA genes in Brazil.
    Abreu GM; Valença DC; Campos M; da Silva CP; Pereira JS; Araujo Leite MA; Rosso AL; Nicaretta DH; Vasconcellos LF; da Silva DJ; Della Coletta MV; Dos Santos JM; Gonçalves AP; Santos-Rebouças CB; Pimentel MM
    Neurosci Lett; 2016 Dec; 635():67-70. PubMed ID: 27777137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of LRRK2 and α-Synuclein in Parkinson's Disease.
    Daher JP
    Adv Neurobiol; 2017; 14():209-226. PubMed ID: 28353286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of LRRK2 and SNCA in autosomal dominant Parkinson's disease in Turkey.
    Kessler C; Atasu B; Hanagasi H; Simón-Sánchez J; Hauser AK; Pak M; Bilgic B; Erginel-Unaltuna N; Gurvit H; Gasser T; Lohmann E
    Parkinsonism Relat Disord; 2018 Mar; 48():34-39. PubMed ID: 29248340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of posttranslational modifications of α-synuclein and LRRK2 in Parkinson's disease: Potential contributions of environmental factors.
    Pajarillo E; Rizor A; Lee J; Aschner M; Lee E
    Biochim Biophys Acta Mol Basis Dis; 2019 Aug; 1865(8):1992-2000. PubMed ID: 30481588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotype-phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35: MDSGene systematic review.
    Trinh J; Zeldenrust FMJ; Huang J; Kasten M; Schaake S; Petkovic S; Madoev H; Grünewald A; Almuammar S; König IR; Lill CM; Lohmann K; Klein C; Marras C
    Mov Disord; 2018 Dec; 33(12):1857-1870. PubMed ID: 30357936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LRRK2 at the Crossroad of Aging and Parkinson's Disease.
    Hur EM; Lee BD
    Genes (Basel); 2021 Mar; 12(4):. PubMed ID: 33805527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. α-Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of Parkinson disease.
    Covy JP; Giasson BI
    Neurotoxicology; 2011 Oct; 32(5):622-9. PubMed ID: 21238487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leucine-rich repeat kinase 2 and alternative splicing in Parkinson's disease.
    Elliott DA; Kim WS; Gorissen S; Halliday GM; Kwok JB
    Mov Disord; 2012 Jul; 27(8):1004-11. PubMed ID: 22528366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of risk factor variants of LRRK2, MAPT, SNCA and TCEANC2 genes in Hungarian sporadic Parkinson's disease patients.
    Boros FA; Török R; Vágvölgyi-Sümegi E; Pesei ZG; Klivényi P; Vécsei L
    Neurosci Lett; 2019 Jul; 706():140-145. PubMed ID: 31085292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylation of α-synuclein and leucine-rich repeat kinase 2 in leukocyte DNA of Parkinson's disease patients.
    Tan YY; Wu L; Zhao ZB; Wang Y; Xiao Q; Liu J; Wang G; Ma JF; Chen SD
    Parkinsonism Relat Disord; 2014 Mar; 20(3):308-13. PubMed ID: 24398085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alzheimer's disease tau is a prominent pathology in LRRK2 Parkinson's disease.
    Henderson MX; Sengupta M; Trojanowski JQ; Lee VMY
    Acta Neuropathol Commun; 2019 Nov; 7(1):183. PubMed ID: 31733655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease.
    Monfrini E; Di Fonzo A
    Adv Neurobiol; 2017; 14():3-30. PubMed ID: 28353276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons.
    Henderson MX; Peng C; Trojanowski JQ; Lee VMY
    Acta Neuropathol Commun; 2018 May; 6(1):45. PubMed ID: 29855356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SNCA but not DNM3 and GAK modifies age at onset of LRRK2-related Parkinson's disease in Chinese population.
    Yang ZH; Li YS; Shi MM; Yang J; Liu YT; Mao CY; Fan Y; Hu XC; Shi CH; Xu YM
    J Neurol; 2019 Jul; 266(7):1796-1800. PubMed ID: 31041581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation.
    Giordana MT; D'Agostino C; Albani G; Mauro A; Di Fonzo A; Antonini A; Bonifati V
    Mov Disord; 2007 Jan; 22(2):275-8. PubMed ID: 17149743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parkinson's disease: SNCA-, PARK2-, and LRRK2- targeting microRNAs elevated in cingulate gyrus.
    Tatura R; Kraus T; Giese A; Arzberger T; Buchholz M; Höglinger G; Müller U
    Parkinsonism Relat Disord; 2016 Dec; 33():115-121. PubMed ID: 27717584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathological Functions of LRRK2 in Parkinson's Disease.
    Jeong GR; Lee BD
    Cells; 2020 Nov; 9(12):. PubMed ID: 33266247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.